Liu Y - Search Results

1

LINC00184 Promotes Ovarian Cancer Cells Proliferation and Cisplatin Resistance by Elevating CNTN1 Expression via Sponging miR-1305.

Han Y, You J, Han Y, Liu Y, Huang M, Lu X, Chen J, Zheng Y. Han Y, et al. Among authors: liu y. Onco Targets Ther. 2021 Apr 19;14:2711-2726. doi: 10.2147/OTT.S280490. eCollection 2021. Onco Targets Ther. 2021. PMID: 33907415 Free PMC article.

2

Upregulation of long noncoding RNA SPRY4-IT1 correlates with tumor progression and poor prognosis in cervical cancer.

Cao Y, Liu Y, Lu X, Wang Y, Qiao H, Liu M. Cao Y, et al. Among authors: liu y, liu m. FEBS Open Bio. 2016 Aug 9;6(9):954-60. doi: 10.1002/2211-5463.12102. eCollection 2016 Sep. FEBS Open Bio. 2016. PMID: 27642559 Free PMC article.

3

Circulating serum exosomal aHIF is a novel prognostic predictor for epithelial ovarian cancer.

Tang X, Liu S, Liu Y, Lin X, Zheng T, Liu X, Qiu J, Hua K. Tang X, et al. Among authors: liu y, liu x, liu s. Onco Targets Ther. 2019 Sep 19;12:7699-7711. doi: 10.2147/OTT.S220533. eCollection 2019. Onco Targets Ther. 2019. PMID: 31571921 Free PMC article.

4

G-5555 synergized miR-485-5p to alleviate cisplatin resistance in ovarian cancer cells via Pi3k/Akt signaling pathway.

Qiao HF, Liu YL, You J, Zheng YL, Chen LP, Lu XY, Du L, Shan F, Liu MH. Qiao HF, et al. J Reprod Immunol. 2020 Aug;140:103129. doi: 10.1016/j.jri.2020.103129. Epub 2020 Apr 14. J Reprod Immunol. 2020. Retraction in: J Reprod Immunol. 2022 Mar;150:103495. doi: 10.1016/j.jri.2022.103495 PMID: 32334286 Retracted.

5

Polyphyllin E Inhibits Proliferation, Migration and Invasion of Ovarian Cancer Cells by Down-Regulating the AKT/NF-κB Pathway.

Liu Y, Cao Y, Kai H, Han Y, Huang M, Gao L, Qiao H. Liu Y, et al. Biol Pharm Bull. 2022 May 1;45(5):561-568. doi: 10.1248/bpb.b21-00691. Epub 2022 Feb 19. Biol Pharm Bull. 2022. PMID: 35185080 Free article.

6

Retraction notice to "G-5555 synergized miR-485-5p to alleviate cisplatin resistance in ovarian cancer cells via Pi3k/Akt signaling pathway" [J. Reprod. Immunol. 140C (2020) 103129].

Qiao HF, Liu YL, You J, Zheng YL, Chen LP, Lu XY, Du L, Shan F, Liu MH. Qiao HF, et al. J Reprod Immunol. 2022 Mar;150:103495. doi: 10.1016/j.jri.2022.103495. Epub 2022 Feb 23. J Reprod Immunol. 2022. PMID: 35219213 No abstract available.

7

MicroRNA-650 suppresses KLF12 expression to regulate growth and metastasis of human ovarian cancer cells.

Lu X, Han Y, Han Y, Huang M, You J, Liu Y, Ding Y, Zheng Y. Lu X, et al. Among authors: liu y. Acta Biochim Pol. 2022 Oct 22;69(4):745-751. doi: 10.18388/abp.2020_5987. Acta Biochim Pol. 2022. PMID: 36272152 Free article.

8

REG3A promotes proliferation and DDP resistance of ovarian cancer cells by activating the PI3K/Akt signaling pathway.

Jiang L, Liu Y, Liu M, Zheng Y, Chen L, Shan F, Ji J, Cao Y, Kai H, Kang X. Jiang L, et al. Among authors: liu y, liu m. Environ Toxicol. 2024 Jan;39(1):85-96. doi: 10.1002/tox.23952. Epub 2023 Sep 4. Environ Toxicol. 2024. PMID: 37665173

9

Integrative analysis from multi-center studies identifies a weighted gene co-expression network analysis-based Tregs signature in ovarian cancer.

Cao Y, Liu YL, Lu XY, Kai HL, Han Y, Zheng YL. Cao Y, et al. Among authors: liu yl. Environ Toxicol. 2024 Feb;39(2):736-750. doi: 10.1002/tox.23948. Epub 2023 Sep 15. Environ Toxicol. 2024. PMID: 37713585

10

Prognostic and immunotherapeutic potential of regulatory T cell-associated signature in ovarian cancer.

Liu Y, Shan F, Sun Y, Kai H, Cao Y, Huang M, Liu J, Zhang P, Zheng Y. Liu Y, et al. Among authors: liu j. J Cell Mol Med. 2024 Apr;28(8):e18248. doi: 10.1111/jcmm.18248. J Cell Mol Med. 2024. PMID: 38520220 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

209,400 results

Search Page

Filters